Menumenu
  • slide

    Current practice insights into the use of biologicals

  • slide

    Rapid access to our in-house patient-centric Database Network

  • slide

    An experienced sparring partner for your European healthcare questions

  • slide

    Dedicated to research real-life health care for the benefit of patients

  • News

    PHARMO’s annual report

    PHARMO’s annual report Each year we develop our annual report to inform the healthcare providers that contribute to the PHARMO Database Network about the research and developments at the PHARMO Institute. The full report is available (in Dutch) he...

    PHARMO Magazine

    Please find below our newest PHARMO Magazine. In our online magazine you can read more about, amongst other things,  our newest additions to the team, our collaboration with Germany and Italy on biologicals in colorectal cancer, data protection by S...

    PHARMO Magazine

    We are proud to offer you the first edition of our new and improved PHARMO Magazine. In this online magazine you can read about our research, our collaborations with universities and other research institutions and upcoming events. Through our st...

  • Events

  • Vacancy

    (Senior) Business development manager

    (Senior) Business Development Manager (locatie Utrecht) Wil je bijdragen aan meer transparantie in de gezondheidszorg? Heb je affiniteit met onderzoek? Heb je internationale commerciële ervaring en een internationaal netwerk in de zorg? Dan ben jij...

  • icon

    What we do

    As an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources PHARMO assists its clients in their decision-making.

  • icon

    What we have

    PHARMO Database Network: we have rapid access to our rich population-based network of databases. Data are derived from different primary and secondary healthcare settings. For our observational studies disease-specific cohorts are created from the various databases.

Publications

  • Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

    Read more
  • No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study

    Read more
  • Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes

    Read more
  • The risk of developing cardiovascular disease is increased for prostate cancer patients who are pharmaceutically treated for depression

    Read more